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Abstract We produced a monoclonal antibody to imidazolones 
A and B, novel advanced glycation end products formed from the 
reaction of 3-deoxyglucosone (3-DG) with the guanidino group of 
arginine. Liquid chromatography/mass spectrometry demon-
strated that the formation of imidazolone A by incubating 3-
DG with arginine is very rapid, reaching a maximum concentra-
tion within 24 h, but the formation of imidazolone B is very slow 
and low in quantity even after 2 weeks. Thus, at physiological 
conditions the formation of imidazolone A is dominant, while 
that of imidazolone B is negligible. Immunochemistry demon-
strated that the imidazolone content in the kidneys of 
streptozotocin-induced diabetic rats was significantly higher than 
in the control rats. Serum levels of 3-DG in the diabetic rats were 
also significantly higher than in control rats. 3-DG attacks the 
arginine residues of the tissue proteins, producing imidazolone at 
high levels in the kidneys affected by diabetic nephropathy. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Glucose reacts non-enzymatically with protein amino 
groups to initiate glycation, the early stage of the Maillard 
reaction. This process begins with the conversion of reversible 
Schiff base adducts to stable, covalently bound Amadori re-
arrangement products. The levels of the Amadori products on 
numerous proteins are elevated in proportion to the degree of 
hyperglycemia in diabetes mellitus. In the intermediate stage 
of the Maillard reaction, the Amadori products can then 
undergo multiple dehydration and rearrangements to produce 
highly reactive carbonyl compounds such as 3-deoxyglucosone 
(3-deoxy-D-erythro-hexos-2-ulose, 3-DG) [1^4-], which reacts 
again with free amino groups, leading to crosslinking and 
browning of the proteins via the formation of advanced gly-
cation end products (AGEs) in the late stage of the Maillard 
reaction. AGEs are characterized by (1) browning, (2) fluo-
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rescence, (3) crosslinking and (4) biological recognition 
through receptors specific for AGEs on macrophages [5,6]. 
Several compounds such as 2-(2-furoyl)-4(5)-(2-furanyl)-l//-
imidazole (FFI) [7], ^-(carboxymethyfJ-L-lysine (CML) [8], 
pyrraline [9], pentosidine [10] and crosslines [11] have been 
proposed as candidates for the structures of AGEs. However, 
FFI [12] was reported not to be AGE but to be an artifact. 
Recently, imidazolone compounds have been isolated from 
the incubation mixture of 3-DG and an arginine derivative as 
novel AGEs [13,14]. It has been reported that 3-DG first 
attacks arginine residues in proteins and then reacts with 
the lysine residues under physiological conditions at 37°C 
and pH 7.4 [2,4]. We produced several clones of monoclonal 
anti-AGE antibodies, and found that one of the antibodies 
specifically reacted with imidazolones. 
Incubation of 3-DG with proteins also leads to the forma-
tion of pyrraline [15] and pentosidine [16], which have been 
identified in human tissue proteins such as collagen and lens 
proteins. 3-DG has also been suggested to be a hydrolysis 
product of fructose-3-phosphate which was identified in the 
lens of diabetic rats [17]. These data suggest that the forma-
tion of 3-DG can occur during the Maillard reaction in vivo 
and be involved in the development of diabetic complications. 
Recently, we developed a sensitive and specific gas chroma-
tography/mass spectrometry using a stable-isotope dilution 
method for measuring 3-DG in human serum, and found 
that serum 3-DG levels were elevated in not only diabetic 
patients [18] but also uremic patients [19,20]. 
In this study we first measured the tissue contents of imi-
dazolone in streptozotocin (STZ)-induced diabetic rats to ex-
amine the pathogenic role of the Maillard reaction in the 
diabetic rats by enzyme-linked immunosorbent assay (ELISA) 
using a monoclonal anti-imidazolone antibody we had pro-
duced. 
2. Materials and methods 
2.1. Samples 
Serum, urine and tissue samples were obtained from 13 diabetic (21 
weeks old; STZ 3 months), 10 non-diabetic (9 weeks old; control 
0 month) and 10 non-diabetic (21 weeks old; control 3 months) Wis-
tar male rats. The diabetic rats were made diabetic at the age of 9 
weeks by intravenous injection of 30 mg/kg STZ. Plasma glucose was 
measured after 1 month, and only animals exhibiting hyperglycemia 
(higher than 20 mM) were selected for the study. Three months after 
injection, the samples of serum, urine, and kidneys were obtained. 
Before cutting out the tissues, perfusion with phosphate buffer (0.01 
M) at about 30 ml/min for 3-5 min was done by catheterization from 
the thoracic aorta through the hepatic vein to remove blood from the 
kidneys. 
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2.2. Serum 3-DG 
Serum 3-DG levels were measured according to the method we have 
previously reported [18]. The intra- and interassay coefficients of var-
iation were 7.8% (n = 5) and 8.6% (n = 5), respectively, at 1.79 uM, 
and 1.6% (n - 5) and 5.0% (n - 5), respectively, at 12.5 u.M. Recoveries 
of 3-DG spiked to a serum sample at concentrations of 3.09 uM and 
12.3 (iM were 109.9±11.5% (mean±S.D., o = 5) and 87.0± 1.6% 
(mean ± S.D., n = 5), respectively. 
2.3. In vitro preparation of AGE-modified proteins and lysine analog, 
and AGE structures 
AGE-modified keyhole limpet hemocyanin (AGE-KLH), AGE-
modified human serum albumin (AGE-HSA), and AGE-modified 
ß2m (AGE-ß2m) were produced by incubating KLH (20 g/1), HSA 
(100 g/1), or ß2m (100 mg/1) (all from Sigma Chemical Company, St. 
Louis, MO, USA), respectively, at 37°C for 1 month (HSA, ß2m) or 
3 months (KLH) with 1 M glucose in 0.2 M phosphate buffer, pH 7.4, 
containing 0.02% NaN3. 
An Amadori product, A^-t-Boc-A^-fructosyl-L-lysine (Fru-Lys), 
was produced by refluxing JV'-t-Boc-L-lysine (100 mg, Kokusan 
Chemical Works, Tokyo, Japan) with glucose (200 mg) in methanol 
(10 ml) at 80°C for 2 h, followed by evaporation and subsequent 
purification with silica column chromatography by eluting with a 
solution composed of methanol/ethyl acetate/acetic acid (60:39:1, v/ 
v). 
A^-^-Tosyl-JV^carboxymefhylJ-L-lysine-methyl ester (Tos-CML-
Me) was synthesized as reported by us [21]. CML derivative of BSA 
(CML-BSA) was synthesized as reported by Kato et al. [22]. Pentosi-
dine was synthesized according to the method of Sell and Monnier 
[23]. Caproyl pyrraline was synthesized according to the method of 
Hayase et al. [24]. Tos-CML-Me, pentosidine and caproyl pyrraline 
were confirmed to be pure using nuclear magnetic resonance spec-
trometry and mass spectrometry. 
3-DG (1 M) was incubated with 2 M A^-p-tosyl-L-lysine-methyl 
ester (Tos-Lys-Me; Sigma Chemical Company, St. Louis, MO, 
USA) in 0.2 M phosphate buffer, pH 7.4, at 37°C for 2 months, to 
examine the reactivity of anti-imidazolone antibody with the incuba-
tion solution. Arginine (0.1 M) was incubated with 0.2 M glyoxal, 0.2 
M methylglyoxal (all from Sigma Chemical Company, St. Louis, MO, 
USA) or 0.2 M 3-DG in 0.2 M phosphate buffer (pH 7.4) at 37°C for 
1 month to further examine the reactivity of anti-imidazolone anti-
body with the incubation solutions. 
2.4. In vitro preparation of imidazolone compounds 
3-DG (0.2 M) was incubated with 0.1 M A^-benzoyl-L-arginine 
amide (Benz-Arg-amide; Nakarai Chemical Co., Kyoto, Japan) in 
0.1 M sodium phosphate buffer, pH 7.4, at 50°C for 132 h [13,14]. 
Two imidazolone derivatives, 2-(4-benzoylamino-5-pentamide)-amino-
5-(2,3,4-trihydroxybutyl)-4(5fl)-imidazolone (a derivative of imidazo-
lone A) and 2-(4-benzoylamino-5-pentamide)-amino-5-(2,3,4-trihy-
droxybutyl)-4-imidazolone (a derivative of imidazolone B) were puri-
fied from the incubation solution by high performance liquid 
chromatography (HPLC). HPLC was performed by monitoring at 
235 nm with a Jasco UVDEC-100-VI detector (Jasco, Tokyo, Japan) 
with a solvent system of 20% methanol, using an ODS 4251-N column 
(Sensyu Kagaku, Tokyo, Japan) [13,14]. 
3-DG (0.2 M) was incubated with arginine (0.1 M) in 0.2 M phos-
phate buffer, pH 7.4, at 37°C for 2 weeks to examine the effect of 
incubation time on the production of imidazolone. Imidazolones A 
and B were formed by incubating 3-DG with arginine (see Fig. 1). 
Incubation solutions were obtained after incubation for 1 h, 6 h, 24 h, 
1 week and 2 weeks, and analyzed by ELISA using anti-imidazolone 
antibody (AG-1) and liquid chromatography/mass spectrometry (LC/ 
MS). 
2.5. LCIMS 
LC/MS was performed using a TSQ-7000 (Finnigan MAT, San 
Jose, CA, USA) with electrospray ionization (ESI). ESI spray voltage, 
capillary temperature and sheath gas (N2), were 4.5 kV, 252°C and 40 
psi, respectively. Incubation solutions of 3-DG with arginine were 
introduced into the mass spectrometer by flow injection with a con-
stant flow (0.5 ml/min) of a solution (water/methanol, 4:1, v/v). The 
ions characteristic for arginine (mh 175), imidazolone A (mlz 319) and 
imidazolone B (mlz 317) were monitored to determine the concentra-
tions of the compounds in the incubation solutions. The levels of 
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Fig. 1. Production of imidazolones A and B by incubating 3-DG 
with arginine. Imidazolone A was first formed, followed by its oxi-
dation to produce imidazolone B. At physiological conditions the 
formation of imidazolone A is dominant, while that of imidazolone 
B is negligible. 
arginine, imidazolone A and imidazolone B were expressed as arbi-
trary units in peak areas of the respective ions. 
2.6. Production of monoclonal anti-imidazolone antibody 
Monoclonal anti-AGE antibodies were produced by immunizing 
mice with AGE-KLH as reported in detail by us [25]. The antibodies 
in the culture medium were screened by sandwich ELISA using anti-
mouse IgG antibody-coated plate, AGE-HSA, and peroxidase-labeled 
anti-HSA antibody, and then two monoclonal clone types of anti-
AGE antibodies (AG-1 and AG-10) were raised. Recently, the epitope 
of AG-10 has been found to be CML [21]. 
2.7. Sample preparation for imidazolone measurement 
Kidneys were washed with PBS and then dissected into small pieces. 
The tissue pieces were kept at 4°C with 1 ml of acetone/chloroform 
(1:1, v/v) overnight. After removing the organic solvent, the defatted 
tissue was incubated at 37°C for 48 h with collagenase type 7 (Sigma 
Chemical Company, St. Louis, MO, USA) in 20 mM Tris-HCl, pH 
7.5, containing 0.1 M CaCl2 (collagenase:defatted tissue, 1:100, w/w). 
After centrifugation at 10 000 X g for 30 min at 4°C, the supernatant 
was diluted five times with water and used for imidazolone measure-
ment. 
2.8. Competitive ELISA for imidazolone 
Sample solution (25 ul) or standard imidazolone A (0.004-0.50 mg/ 
1) was incubated at room temperature for 1 h in an AGE-HSA (0.01 g/ 
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Fig. 2. Competitive ELISA demonstrating the specificity of the monoclonal anti-imidazolone antibody (AG-1). Derivative of imidazolone A: 
2-(4-benzoylamino-5-pentamide)-amino-5-(2,3,4-trihydroxybutyl)-4(5//)-imidazolone; derivative of imidazolone B: 2-(4-benzoylamino-5-pentam-
ide)-amino-5-(2,3,4-trihydroxybutyl)-4-imidazolone. 
l)-coated microplate with PBS containing 0.25% BSA (50 ul) and 
peroxidase-conjugated anti-imidazolone antibody (AG-1). After wash-
ing four times with PBS, o-phenylenediamine (100 ul) was added to 
the microplate. Reaction was stopped by adding 1.6 M H2SO4 (100 
ul), and absorption at 492 nm was measured using 620 nm as control. 
Imidazolone contents were expressed as arbitrary units (imidazolone 
A umol per g protein measured by Lowry method). Recoveries of 
AGE-HSA added to the extract of kidney at concentrations of 10.9 
mg/1 and 21.5 mg/1 were 89.3 ±16.2% (n = 4) and 86.3 ±7.8% (« = 4), 
respectively. Intraassay coefficients of variation for imidazolone were 
12.1% (n = 8), 10.5% (n = 8), 4.8% (w = 8) and 3.6% (71 = 8) for four 
kidney samples from one control (0 month), one control (3 months), 
and two STZ (3 months) rats, respectively. 
2.9. Measurement of the other biochemical parameters 
Serum glucose was measured by an autoanalyzer using the Merck 
liquid GLU test kit (Kanto Kagaku, Tokyo, Japan). Serum fructos-
amine was measured with the fructosamine test Rosch II (Japan 
Rosch, Tokyo, Japan). Serum and urine creatinine were measured 
with a Beckman creatinine analyzer (Beckman Instruments) using 
the Jaffé reaction method. Creatinine clearance was measured by col-
lecting 24 h urine. Urinary protein was measured with a micro TP-test 
kit (Wako Pure Chemical, Osaka, Japan) using the pyrogallol red 
method. 
3 . Results 
3.1. Characterization of monoclonal anti-imidazolone antibody 
The specificity of the ant i -AGE antibody (AG-1) was 
studied using the competitive ELISA (Fig. 2). The antibody 
reacted with the AGE-modified proteins such as AGE-HSA 
and AGE-ß 2 m, demonstrating that the ant i -AGE antibody 
recognizes a common epitope of AGE-modified proteins. 
The antibody did not react with Fru-Lys, an Amador i prod-
uct. The antibody did not react with Tos-CML-Me, C M L -
BSA, caproyl pyrraline or pentosidine (Fig. 2). Thus, the 
ant i -AGE antibody was demonstrated not to react with Ama-
dori product, or well-known A G E structures such as C M L , 
pyrraline, or pentosidine. 
The epitope of the ant i -AGE antibody (AG-1) was con-
cluded to be imidazolone, since the antibody reacted with 
benzamide derivatives of imidazolones A and B (Fig. 2) and 
the incubation solutions of 3 D G and Benz-Arg-amide, but did 
not react with 3 D G or Benz-Arg-amide (Fig. 3). The antibody 
did not react with the incubation solution of 3-DG and Tos-
sa 
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Fig. 4. ESI mass spectra of the incubation solutions of 3-DG and arginine incubated for 1 h and 2 weeks. 
Lys-Me, the major product of which was CML. The antibody 
reacted with the incubation solution of arginine and 3-DG, 
but did not react with the incubation solutions of arginine and 
the other 1,2-dicarbonyl compounds (glyoxal or methylglyox-
al) (Fig. 3). These results demonstrate that the epitope of the 
antibody is the imidazolone ring coupling with at least a par-
tial structure of 3-DG, and that the direct precursor of imi-
dazolone is 3-DG but not the other dicarbonyl compounds 
(glyoxal or methylgyoxal). 
3.2. Effect of incubation time on the formation of imidazolone 
Fig. 4 shows ESI mass spectra of the incubation solutions 
of 3-DG and arginine after incubation for 1 h and 2 weeks. 
The ion peak at miz 175 (M+H)+ represents arginine (molec-
ular weight 174), the ion peaks at miz 319 (M+H)+ and miz 
317 (M+H)+ represent imidazolone A (molecular weight 318) 
and imidazolone B (molecular weight 316), respectively. 3-DG 
could not be ionized by ESI, providing no ion peak in the 
mass spectra. Fig. 5 shows the mass chromatograms of argi-
nine, imidazolone A and imidazolone B in the incubation 
solutions. Fig. 6 summarizes the time course of imidazolone 
formation as demonstrated by ELISA and LC/MS. As argi-
nine level decreased rapidly, imidazolone level increased. A 
considerable amount of imidazolone A was formed even after 
incubation for 1 h, and its formation reached a maximum 
within 24 h. However, imidazolone B is formed very slowly 
and low in quantity, reaching a maximum level after incuba-
tion for 2 weeks. Time course of imidazolone formation esti-
mated by ELISA was comparable to that by LC/MS, demon-
strating that ELISA using the antibody is specific for 
imidazolone. 
3.3. Imidazolone content in the kidneys 
Table 1 shows the imidazolone content in the kidneys, and 
the levels of serum 3-DG and the other parameters in STZ-
induced diabetic and normal rats. The diabetic rats showed 
nephropathy with proteinuria, hypoproteinemia, hyperlipide-
mia and reduced creatinine clearance. Imidazolone contents in 
kidneys were significantly increased in the diabetic rats as 
compared with control (3 months) rats. 
T. Niwa et al. I zFEBS Letters 407 (1997) 297-302 301 
100 
100 
Arginine 
(m/z 175) 
l h 6 h 24 h l w 2 w 
1 
Imidazolone A 
. (m/z 319) 
100 -i Imidazolone B 
(m/z 317) 
T-m-r 
i k i k L 
3:20 
I i i i ■ T " i i i i I 
6:40 
-n 
E+07 
1.909 
, , , ,h ft 1 , 
. E+07 
3.236 
. E+05 
8.651 
10:00 13:20 16:40 
LC/MS Analysis Time (min) 
Fig. 5. Mass chromatograms of arginine, imidazolone A and imidazolone B in the incubation solutions. 
4. Discussion 
This is the first study demonstrating that imidazolone is a 
common epitope of AGE-modified proteins and is present in 
vivo at high levels in the kidneys of diabetic rats with neph-
ropathy. Since 3-DG reacts with arginine residues in proteins 
to induce their imidazolone modification, elevated serum lev-
els of 3-DG result in high kidney contents of imidazolone in 
the STZ diabetic rats with nephropathy. The imidazolone 
modification of proteins in kidneys may be involved in the 
pathogenesis of diabetic nephropathy. 
Formation of imidazolone A by incubating 3-DG with ar-
ginine is very rapid, reaching a maximum concentration with-
in 24 h. However, the formation of imidazolone B is very slow 
and low in quantity (a few percent of the imidazolone A level) 
even after incubation for 2 weeks. This appears to be incon-
sistent with the report that the amount of imidazolone B 
formed was higher than that of imidazolone A after incuba-
tion for 6 days [14]. This discrepancy can be explained by the 
difference in the incubation temperature. In that report the 
incubation was performed at 50°C and pH 7.4 [14], while in 
our experiments at 37°C and pH 7.4. Our study demonstrates 
that at physiological conditions the formation of imidazolone 
A is dominant, while that of imidazolone B is negligible. 
Thus, imidazolone A is the dominant antigen detected by 
ELISA using anti-imidazolone antibody (AG-1) in the kid-
neys of diabetic rats. 
Formation of imidazolone ring was reported in the incuba-
tion solution of an arginine residue and methylglyoxal [26]. 
However, our anti-imidazolone antibody does not react with 
the incubation solution of arginine and methylglyoxal (or 
glyoxal), demonstrating that the antibody does not recognize 
the imidazolone ring itself. Since our antibody reacts with the 
incubation solution of an arginine residue and 3-DG, the anti-
body recognizes the imidazolone ring coupling with at least 
partial structure of 3-DG. The antibody is specific for 3-DG-
derived imidazolone and not for methylglyoxal (or glyoxal)-
derived imidazolone. Thus, the imidazolone detected using 
our antibody was formed by 3-DG but not by methylglyoxal 
nor glyoxal. 
The elevated serum levels of 3-DG in the diabetic rats may 
be due to the increased production of 3-DG via the Maillard 
reaction resulting from hyperglycemia. However, serum 3-DG 
did not correlate with fructosamine or glucose, supporting the 
role of the reducing enzymes in determining the serum levels 
of 3-DG in the diabetic rats. 3-DG is normally detoxified by 
reducing enzymes to 3-deoxyfructose, which is then excreted 
to urine [27]. In monkey the reducing enzymes of 3-DG are 
composed of aldehyde reductase, aldose reductase and dihy-
drodiol dehydrogenase, and kidney showed the highest activ-
ity of the reducing enzymes of 3-DG among various tissues 
[28]. 3-Deoxyfructose has been detected in human urine and 
plasma [29] at high concentrations in diabetic patients [30]. 
The ability to detoxify 3-DG by the reducing enzymes may 
provide a genetic basis for differences in the severity of dia-
betic complications and age-related pathologies. 
Pyrraline was detected in sclerosed glomeruli from diabetic 
patients by immunohistochemistry using an anti-pyrraline 
antibody [31]. Since pyrraline is also formed by reacting lysine 
residue with 3-DG, elevated serum 3-DG levels in diabetes 
Table 1 
Levels of tissue imidazolone, serum 3-DG and the other parameters in streptozotocin (STZ)-induced diabetic rats and control non-diabetic rats 
Imidazolone content (arbitrary units) 
Kidney 
Serum 
3-DG (uM) 
Glucose (mM) 
Fructosamine (u.M) 
Creatinine (mM) 
Creatinine clearance (ml/s) 
Urine protein (mg/day) 
Body weight (g) 
Control (0 month) 
»=10 
0.26 ±0.02 
1.04 ±0.08 
8.33 ±0.39 
149 ± 2 
46.9 ±0.2 
0.019 ±0.001" 
11.3 ±2.9 
228 ± 2 " 
Control (3 months) 
«=10 
0.31 ±0.01 
1.23 ±0.13 
7.66 ±0.28 
149 ±2 
48.6 ±0.2 
0.026 ±0.001 
8.0 ±0.7 
403 ±7 
STZ (3 months) 
«=13 
0.40 ±0.02" 
3.46 ±0 .23" 
31.4 ±0.88" 
310 ± 6 " 
62.8 ±7.1 
0.018 ±0.002" 
63.6 ± 7 . 1 " 
197 ± 5 " 
All results are expressed as mean ± S.E. 
*P<0.05, " P < 0 . 0 1 as compared with control (3 months) by Student's ï-test. 
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Fig. 6. Time course of the production of imidazolones as demon-
strated by ELISA and LC/MS. 
may lead to the increased modification of the extracellular 
matrix proteins with pyrraline in diabetic glomerulosclerosis. 
We first demonstrated that imidazolone, a chemically-identi-
fied novel AGE, was present at high levels in the kidneys of 
diabetic rats. Since the direct precursor of imidazolone is 3-
DG but not the other dicarbonyl compounds (glyoxal or 
methylglyoxal), the elevated serum levels of 3-DG in diabetes 
result in the increased modification of extracellular matrix 
proteins in the kidneys with imidazolone. Thus, this study 
provides conclusive evidence that 3-DG is involved in the 
AGE modification of tissue proteins in diabetic kidneys. 
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